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Abstract
Background: Numerous vitamin-D analogs exhibited poor response rates, high systemic toxicities and hypercalcemia in
human trials to treat cancer. We identified the first non-hypercalcemic anti-cancer vitamin D analog MT19c by altering the
A-ring of ergocalciferol. This study describes the therapeutic efficacy and mechanism of action of MT19c in both in vitro and
in vivo models.
Methodology/Principal Finding: Antitumor efficacy of MT19c was evaluated in ovarian cancer cell (SKOV-3) xenografts in
nude mice and a syngenic rat ovarian cancer model. Serum calcium levels of MT19c or calcitriol treated animals were
measured. In-silico molecular docking simulation and a cell based VDR reporter assay revealed MT19c–VDR interaction.
Genomewide mRNA analysis of MT19c treated tumors identified drug targets which were verified by immunoblotting and
microscopy. Quantification of cellular malonyl CoA was carried out by HPLC-MS. A binding study with PPAR-Y receptor was
performed. MT19c reduced ovarian cancer growth in xenograft and syngeneic animal models without causing
hypercalcemia or acute toxicity. MT19c is a weak vitamin-D receptor (VDR) antagonist that disrupted the interaction
between VDR and coactivator SRC2-3. Genome-wide mRNA analysis and western blot and microscopy of MT19c treated
xenograft tumors showed inhibition of fatty acid synthase (FASN) activity. MT19c reduced cellular levels of malonyl CoA in
SKOV-3 cells and inhibited EGFR/phosphoinositol-3kinase (PI-3K) activity independently of PPAR-gamma protein.
Significance: Antitumor effects of non-hypercalcemic agent MT19c provide a new approach to the design of vitamin-D
based anticancer molecules and a rationale for developing MT19c as a therapeutic agent for malignant ovarian tumors by
targeting oncogenic de novo lipogenesis.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death
from gynecologic malignancies. Early-stage cancers are mostly
asymptomatic, and most of the diagnoses at presentation detect
established regional or distant metastases [1]. The majority of the
patients will experience recurrent disease, as well as resistance to
chemotherapeutic agents. The low survival rate of advanced stage
ovarian cancer has made early detection, understanding the
etiology of the disease and the targeting of specific characteristic
features, as the top priorities in cancer research [1].
Increased de novo fatty-acid synthesis is a hallmark of cancer
[2,3]. Otto Warburg first observed enhanced anaerobic glycolysis
in cancer cells [4]. Normal human tissues use dietary fats for
synthesis of new structural lipids, whereas incessantly proliferating
cancer cells for unknown reasons avoid utilization of dietary fats
and carry out independent de novo fatty acid synthesis to
continually provide for membrane production, energy generation
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34443
         and lipid modification of proteins [4]. De novo fatty-acid synthesis
involves two key enzymes; acetyl Co-A carboxylase (ACC) and
fatty-acid synthase (FASN). ACC carboxylates acetyl-CoA to form
malonyl CoA. The malonyl-CoA product is further converted by
FASN to long-chain fatty acids. Newly synthesized fatty acids are
stored by lipolytic PPAR-gamma to avoid fatty acid toxicity.
Therefore, deregulated functions of lipogenic enzymes FASN and
ACC involved in de novo fatty-acid synthesis in conjunction with
lipolytic PPAR-gamma play an important role in promoting tumor
cell survival at multiple levels.
Numerous studies have shown overexpression of FASN in
human epithelial ovarian cancer (EOC) [5–8] and cancers of
breast [9], prostate [10], colon [11], lung [12], endometrium [13]
and papillary thyroid [14]. An oligonucleotide microarrays
consisting of more than 6,000 human genes identified fatty acid
synthase (FASN) as a potential therapeutic or molecular target in
EOC [15]. Subsequently, a pharmacological targeting of FASN by
the natural product cerulenin and a synthetic molecule C75
suppressed growth of ovarian and breast cancer in animal models
[16–17]
In the current study, we show that MT19c is a new class of
antitumor agent that targets critical components of de novo fatty
acid synthesis machinery in ovarian cancer xenograft tumors and
ovarian cancer cells. MT19c is a novel vitamin-D2 derived agent
that exerted no hypercalcemic effects and displayed very high
safety indices in nude mice. MT19c is a weak VDR antagonist that
disrupts VDR-coactivator interactions and did not exhibit classical
calcitriol-VDR interactions [18]. At low doses of MT19c, ovarian
xenograft tumors or syngeneic rats showed partial to complete
response and extended the survival rate significantly compared to
control animals. This study outlines a new approach to design safe
and efficacious class of vitamin-d anticancer agents that are devoid
of hypercalcemia as well as classical vitamin-D type toxicities.
Moreover, data provided herein verified that current emphasis on
targeting de novo fatty acid synthesis enzyme machinery to treat
ovarian cancer is a viable approach to treat human ovarian
cancer, and based on this study MT19c has been identified as a
promising candidate for clinical evaluation in human ovarian
cancer patients.
Results
Efficacy studies of MT19c in animal EOC models
The anti-tumor efficacy of MT19c (Fig. 1A) was studied using
human EOC cell derived xenografts in nude (NU/NU) mice as
well as rat ovarian cancer based syngeneic rat model in Fisher-344
rats. For the first study SKOV-3 cells suspended in matrigel were
inoculated subcutaneously in one flank of each animal. Animals
were assigned to a treatment (n=20) or a control group (n=10).
Vehicle or MT19c (5 mg/kg bwt) was administered IP every other
day for 60 days to mice bearing SKOV-3 derived tumors. Animals
were weighed (Figure 1B, lower panel) and tumor size measured
(Figure 1B, upper panel) every 5 days. Normal weight gain for
both vehicle and drug treated mice was observed during
treatment. Tumor size increased in the control animals with an
average 2-fold increase of tumor diameter during the trial period.
In the treatment group, tumor size decreased significantly during
the last 15 days of treatment with 5 of 8 animals showing complete
response (Fig. 1B, upper panel). Animal survival rates were
significantly different between treatment and control groups
(p=0.0001, Fig. 1C) based on Kaplan-Meier analysis. During
the evaluation period, vehicle treated mice reached the end point
(10 mm tumor diameter) within 20 days of treatment whereas a
portion of MT19c treated animals survived until study end.
As an independent approach to determine the anti-cancer
activity of MT19c in vivo we employed a well defined syngeneic rat
EOC model [19] Fisher 344 rats were divided in two treatment
groups of 3 animals each and one control group. NuTu-19 rat
EOC cells were injected IP. After 3 weeks, either 0.1 or 0.5 mg
MT19c/kg bwt or vehicle were injected IP daily. An average of
22 ml of ascitic fluid was collected in control animals at study
endpoint (Fig. 1D, ascites volume). Multiple small tumors (0.1–
1.5 cm in diameter) were observed on the omentum, bowel,
diaphragm, peritoneal wall, and surface of all other abdominal
organs. MT19c treatment dose-dependently reduced average
ascites formation at 0.5 mg/kg bwt and suppressed tumor nodule
formation. Similarly, MT19c treatment dose-dependently reduced
the average omental weight (Fig. 1D). In this study we used a very
low dose of MT19c as compared to the acute toxicity study
(400 mg/kg bwt) or the above mice xenograft model and long-
term toxicity study (5 mg/kg bwt; 106 greater). Remarkably, at
the dose of 0.5 mg MT19c/kg bwt all 3 animals treated showed
tumor regression (Fig. 1D, response index). One animal showed a
complete response. Animal weights in both control and treatment
groups increased during this experiment (Fig. 1D).
MT19c effects on serum calcium levels and toxicity
studies in animal models
Currently known calcitriol/vitamin-D3 analogs cause hypercal-
cemia. We therefore investigated if MT19c can cause hypercal-
cemia in animals despite altered A-ring conformation. In animals,
MT19c did not cause hypercalcemia during 35days of animal trial.
Calcitriol showed significantly higher serum calcium levels
(15.5 mg/dL) at the end of treatment than MT19c treated mice
(,10 mg/dL) which was closer to calcium levels in control group
(p,0.05) (Fig. 2A).
An acute toxicity study to determine safety of MT19c was
performed by the National Cancer Institute (NCI) in athymic nude
mice. MT19c was administered intraperitoneally (IP) at doses 400,
200, 100 mg/kg bwt (one animal/dose) and animals were
monitored for a period of 13 days (Fig. 2B) to record any
observable toxicity (see Supporting Information S1). MT19c did
not show any toxicity at any of three doses tested. Acute toxicity
measures the concentration that will adversely affect the animal’s
health, and lethality is the most common endpoint.
MT19c does not affect VDR transcription in cells
MT19c showed a weak antagonistic effect in a fluorescence
polarization assay using the VDR ligand binding domain and a
fluorescent labeled coactivator peptide [20]. To determine
transcriptional regulation of VDR in cells upon MT19c treatment
we employed a cell-based functional-VDR-reporter assay (Gene-
BLAzerH Technology, www.invitrogen.com) using transformed
HEK293 cells (see Supporting Information S1). These HEK293T
cells express a fusion protein of VDR-LBD–GAL4 DNA-binding
domain, which is activated by calcitriol and induces transcription
of a beta-lactamase reporter gene. The transcriptional activation
of VDR in the presence of MT19c was determined after 5 hr pre-
treatment with the control calcitriol (0.1 pM–1 nM) (Fig. 2C; left
panel) or MT19c (1 nM–1 mM) (Fig. 2C; middle panel). Calcitriol
caused VDR-activation at 10 pM (IC50,30 pM). MT19c showed
no agonistic activity at the concentrations tested. To analyze
antagonistic effects, cells stimulated by calcitriol (120 pM) were
treated with MT19c (1 nM–50 mM) (Fig. 2C; right panel) for 5 h.
MT19c inhibited calcitriol-induced VDR-activation only at
relatively high concentrations (IC50,30 mM). Thus MT19c
emerged as an extremely weak VDR antagonist not reaching
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potent VDR antagonist than TEI-9647 or ZK159222 [21].
Molecular Docking Simulation (MDS) of VDR and MT19c
interaction
Most of the currently known calcitriol/vitamin-D3 analogs are
VDR agonists. For molecular insight into a possible interaction
between MT19c with the VDR we employed a MDS based on the
structure of MT19c and the VDR liganded to calcitriol (PDB ID:
1DB1) [22] utilizing the AutoDock 4.0 program [23]. Possible
protein-ligand complexes were selected based on their binding
free-energy and the conformation with the lowest docked energy
was chosen as a possible candidate for MT19c/VDR interaction.
Fig. 3A depicts the MDS for VDR and calcitriol (left panel) or
MT19c (right panel). In the binding pocket of VDR, the residues
that are in contact with calcitriol were used as a reference (Fig. 3B)
and for MT19c the same residues were chosen to characterize
interactions. We observed that MT19c acquired an inverted
accommodation in VDR ligand binding domain compared to
calcitriol. MT19c is the first vitamin-D class of molecule to
demonstrate this unique VDR-LBD interaction. Up-side accom-
modation of MT19c in VDR-LBD was highly consequential that
disabled the classical calcitriol-VDR like interactions which define
the genomic functions of vitamin-D. Further, the key space
between helices 11 and 12 in the VDR ligand-binding domain
where calcitriol or the antagonist ZK168281 side chain (C-25)
Figure 1. Chemotherapeutic properties of MT19c in vivo. (A) chemical structure of MT19c. (B) Anti-cancer activity of MT19c in an EOC
model in mice. Nude mice (20 treated and 10 controls) bearing SKOV-3 derived tumor xenografts were dosed (IP) with either vehicle control or
MT19c (5 mg/kg bwt) on alternate days for 60 days. Tumor size was calculated (upper panel) using a caliper every 5 days and weight recorded (lower
panel). (C) Kaplan-Meier survival analysis. Kaplan-Meier survival analysis for MT19c and vehicle-treated mice was performed using STATA 9
(StataCorp, College Station, TX) and SAS 9.1 software (SAS Institute, Cary, NC). (D) Efficacy of MT19c in a syngeneic EOC model in rats. Fisher
344 rats (3 animals/treatment group) were injected IP with rat EOC cells NuTu-19. After 3 weeks, either MT19c (100 or 500 mg/kg bwt) or vehicle were
injected IP daily for 12 days. Tumor tissues were harvested and omental weight (D-1), ascitic volume (D-2) and body weight (D-3) recorded. Mean
omental weight and volume were compared by Student’s T-test with unequal variances. The lower panel depicts the response index (D-4).
doi:10.1371/journal.pone.0034443.g001
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(Fig. 3D, right panel). Interestingly, MT19c revealed a closer
hydrogen binding between its carbonyl of the A-ring with VDR
residue H397 (2.05 A ˚) (Fig. 3E, right panel) as compared to the 25-
hydroxy group of calcitriol (2.8 A ˚) (Fig. 3E, left panel). Multiple
effects described above including the enlarged altered A-ring
structure of MT19c that disrupted the natural conformation of
helices 11,12 and 13 upon inverted entry in the VDR-LBD,
Figure 2. Characteristics of MT19c as a vitamin-D3 derivative. (A) Serum calcium levels in mice after MT19c treatment. 8 mice each
were treated with MT19c(5 mg/kg bwt) or calcitriol (10 ug/kg bwt) or vehicle (EtOH) for 35 days, blood collected and serum calcium analyzed at day
35. Change in mean serum calcium was significant (P,0.05) compared between groups by Student’s T-test with unequal variances (B) Acute
toxicity study of MT19c. MT19c or vehicle was administered to nude mice and animals were monitored for any observable toxicity. (C) MT19c in
a VDR-agonist or antagonist screening. VDR-over-expressing VDR-UAS-bla HEK 293T cells were treated for 5 h with calcitriol/vitamin-D3
(0.1 pM-1 nM; left panel) or MT19c (1 nM-1 mM; middle panel) and VDR-activation was analyzed. To analyze antagonistic effects the assay was carried
out (SelectScreenH Cell-based Nuclear Receptor Profiling Services: http://www.invitrogen.com) after cell stimulation with calcitriol/vitamin-D3
(120 pM) and treatment with MT19c (1 nM-1 mM; right panel;) for 5 h. (D) Summary of salient features of MT19c and related compounds.
Comparison of MT19c with to calcitriol and other clinically relevant vitamin-d derivatives.
doi:10.1371/journal.pone.0034443.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34443Figure 3. Molecular Docking Simulation of VDR and MT19c. (A) 3D structures of VDR/calcitriol and VDR/MT19c complexes. Left panel:
VDR/calcitriol complex (Calcitriol in center, helix 11=white color). Right panel: VDR/MT19c complex (MT19c in center, 11=light green). MDS was
carried out using the AutoDock 4.0 program with the structure of MT19 and of calcitriol-liganded VDR provided by the Protein Data Bank. Images of
structures were generated using UCSF Chimera. (B) Sequence of VDR ligand binding site. Yellow color code represents helices in the structure.
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of VDR-LBD, and distortion in helices 11, 12 and 13 that enables
VDR-coactivator interactions may explain why MT19c is non-
hypercalcemic in animals [21].
MT19c inhibits EGFR signaling both in vitro and in vivo
but does not affect PPAR-gamma expression
To identify the molecular targets of MT19c in ovarian cancer
cells, a Gene Set Enrichment Analysis (GSEA) analysis of the
genome wide mRNA of vehicle treated (control) and MT19c
treated tumors on day-8, day-16 and day-30 was conducted in
triplicates using Affymetrix Human Gene 1.0 ST Array (Affyme-
trix, Santa Clara, CA). The expression data has been deposited at
address www.ncbi.nlm.nih.gov (acc=GSE23616). MT19C treated
xenograft tumors consistently showed lower expression levels for
genes involved in energy metabolism (p,0.00000000055). Based
on expression levels with higher statistical significance
(p=0.00000005; cutoff point), we clustered the key metabolic
genes that were affected by an Ingenuity Pathway Analysis (IPA).
The differential expression of EGFR, PI3K, PRKAA2, THRSP,
SREBF1, Malonyl Co-A carboxylase, Acetyl CoA carboxylase and
Fatty acid synthase in control and treatment group on the day-8,
day-16 and day-30 is shown in Fig. 4A.
Cancer cells organize the energy requirement by reorienting
lipogenic/lipolytic metabolic balance to provide for and sustain
the cancer growth by redefining functions of EGFR, PPAR-
gamma, and fatty acid synthesis and glycolysis machinery [24].
Targeting EGFR and other components of metabolism has been,
therefore, postulated to improve ovarian cancer therapy outcome
[6,25]. To understand the effect of MT19c on EGFR and its
downstream signaling cascade in ovarian cancer, we investigated
the effect of MT19c on EGFR and PI-3kinase activity in SKOV-3
cells by western blot analysis, microscopy and an in vitro PI-3kinase
activity assay.
Gene expression (GSEA) analysis showed that MT19c sup-
pressed EGFR expression in the tumors treated on the day-8.
Moreover, tumors treated up to day-30 showed significant
downregulation of EGFR while minor activation of EGFR in
tumors treated up to day-16 indicating counteraction effort against
the drug action was observed (Fig. 5A). Next, we validated the
microarray data on EGFR by immunohistochemical analysis of
treated SKOV-3 xenografts treated with vehicle or MT19c (5 mg/
kg bwt). The slides of snap frozen harvested tumors from the
vehicle or drug treated animals in the Fig. 1B were immuno-
stained with an FITC-EGFR antibody (R&D systems, MN, USA)
and counter-stained with DAPI dissolved in Vecta-shield mount-
ing media (Vector labs, CA). A confocal microscopy of the
phospho-EGFR stained control tumors showed strong cytosolic
staining and densely packed nuclei, while MT19c treated tumors
demonstrated significantly reduced quantitative staining or
expression compared to control (Fig. 4B).
To study the functional effect of MT19c on EGF receptor
expression in ovarian cancer cells we examined EGFR localization
in SKOV-3 cells in vitro upon treatment with MT19c. SKOV-3
cells were treated with MT19c (100 nM) or calcitriol (2 mM) for
12 hr in serum free conditions. The cells were processed as
described in Material and Method section. A microscopic
examination of the vehicle treated cells showed clear and intact
cellular morphology with transmembrane EGFR staining in
company with few nuclei densely stained (Fig. 4C, upper left
panel). A DAPI staining also showed intact structural integrity of
DNA and chromatin (Fig. 4C, upper right panel). Contrary to
vehicle, calcitriol treated cells showed highly intense and specific
nuclear staining due to nuclear translocalization and demonstrated
lack of transmembrane staining (Fig. 4C, middle panels). On the
other hand, contrary to calcitriol, MT19c treatment did not
promote EGFR nuclear translocalization and a strong transmem-
brane EGFR staining among cell population similar to vehicle
treated cells were observed (Fig. 4C, lower panels). Few nuclei with
dense nuclear stain in MT19c treated cell population, in fact, were
reminiscent of apoptosis than nuclear translocation. It was noted
that xenograft tumors showed stronger cytosolic staining than
transmembrane staining observed for cultured SKOV-3 ovarian
cancer cells, possibly indicating the differential tumor micro-
environment of the both type of cells (Fig. 4B and 4C). A western
blot analysis of the drug treated SKOV-3 cells showed that
MT19c suppressed EGFR activation within 12 hrs of treatment
(Fig. 4C, left panel).
Since EGFR directly regulates many critical functions of PI-
3kinase [5], to analyze PI-3kinase activity in SKOV-3 cells upon
application of MT19c (250 nM) we performed a PI-3kinase
activity [26]. The PI3-kinase (PI3K) pathway regulates many
cellular processes such as cell metabolism, cell survival, and
apoptosis in cancer and phosphotidylionositol-3,4,5-triphosphate
(PIP-3) is the key mediator of PI-3kinse signal transduction [27].
PIP-3 is synthesized from phosphotidylionositol-4,5-diphosphate
(PIP-2) [28]. Based on our immunoprecipitation assay, we
observed that MT19c treatment (250 nM) downregulated PIP-3
production significantly within 12 hrs compared to control
(Fig. 4D). The pixel density measurement of loading spot
representing PIP-3 amount of the control lysate eluted via thin
layer chromatography (TLC) was 14480 units whereas the MT19c
treated sample showed 9 fold less quantitative synthesis of PIP-3
(pixel density 1304) (Fig. 4D, lower panel). Surprisingly, PIP-3
production was strongly upregulated 2-fold within first 3 hours of
treatment indicating pro-survival pressure upon the application of
the drug. To further understand the effect of MT19c on the
expression of PI-3kinase, a Western blot was carried out. MT19c
(250 nM) treatment showed downregulation of PI-3kinase phos-
phorylation in SKOV-3 cells within 12 hours, (Fig. 4C, left panel).
MT19c does not affect PPAR-gamma component of lipid
metabolism in ovarian cancer cells
EGFR overexpression activates PPAR-gamma function in
cancer cells to protect them from palmitate toxicity [24]. PPAR-
gamma is a potential target for the prevention and treatment of
cancer [29]. We examined the interaction of MT19c with nuclear
receptor PPAR-gamma by conducting a fluorescence polarization
assay. In the absence of PPAR-gamma agonist (GW949) we did
not observed an interaction between PPARc and coactivator
protein DRIP2. Similarly, in the presence of agonist GW949 no
disruption of the interaction between VDR and DRIP2 was
observed.
Green color code represents amino acids with direct interaction to the ligand (calcitriol). (C) Interaction comparison. Left panel: Interaction
between Leu227 and calcitriol. Right Panel: Interaction between Leu227 and MT19c. (D) Comparison of helix 12 and helix 11 interactions with
ligands. Left panel: Interaction between helix 11 (purple), helix 12 (yellow), and calcitriol. Right Panel: Interaction between helix 11 (white), helix 12
(yellow) and MT19c. In both panels interaction between His397 on helix 11 and ligand is depicted. (E) Distances between His 397 and ligands.
Left panel: Interaction between His397 and calcitriol. Right Panel: Interaction between His397 and MT19c.
doi:10.1371/journal.pone.0034443.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34443Figure 4. Cellular and biochemical effects in MT19c treated EOC cells in vitro. (A) Genomic analysis of naı ¨ve or MT19c treated
xenograft tumors. SKOV-3 xenografts were treated with vehicle or MT19c (5 mg/kg bwt) and tumor tissue were harvested on day-8, 16 and 30. The
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xenograft tumors
EGFR/PI-3Kinase enhances lipogenesis in cancer cells by
activating lipogenic fatty acid synthase (FASN) machinery in
conjunction with PPAR c [5]. Overexpression of FASN in human
epithelial ovarian cancer (EOC) has been shown [7–10]. An
oligonucleotide microarrays screen identified fatty acid synthase
(FASN) as potential molecular target in EOC [17]. Genome-wide
mRNA analysis of the naı ¨ve and MT19c treated xenograft tumors
clearly identified MT19c action on FASN expression in MT19c
treated ovarian cancer xenograft (p=0.00000000055) (Fig. 4A)
[30].
We observed via immunoblotting that MT19c treatment
suppressed expression of FASN and acetyl Co-A carboxylase
(ACC) in SKOV-3 cells (Fig. 5A) time dependently. We examined
whether MT19c regulates FASN and ACC in treated xenograft
tumors. Harvested xenografts of the naı ¨ve and MT19c treatment
groups were immuno-stained with FASN antibody and analyzed
by fluorescence microscopy to distinguish the FASN staining in
control group versus treatment group. While vehicle treated
tumors showed intense and homogenous staining around lipid
droplets embedded in the tissues (Fig. 5D, left upper panel),
MT19c treated tumors showed significant lack of staining or
partial/residual staining (Fig. 5E, right upper panel). We observed
the presence of 2 fatty fields in the whole tissue section that were
densely stained in the control. Similarly only two fatty fields were
detected in the drug treated xenograft section and the FASN
staining around them was significantly lower than vehicle treated
control tissues. We carried out fluorescence intensity measure-
ments of whole tissue sections of both control and drug treated
tissue and calculated the mean and the Integrated Optical Density
(IOD). The fluorescence intensity of the drug treated tissue showed
a mean value of 11697 units and 4.14 units of IOD compared to
22805 units of mean and 17.15 units of IOD observed for vehicle
treated xenograft tissue indicating significant reduction in staining
in MT19c treated xenograft tumors.
Acetyl CoA-carboxylase (ACC) is the rate-limiting enzyme for
the long chain fatty acid synthesis and is also a molecular target of
much current research interest for the treatment of obesity and
cancer [4,5]. Harvested xenografts of the naı ¨ve and MT19c
treatment groups were immunostained with phospho-ACC
antibody and analyzed by fluorescence microscopy to distinguish
the ACC staining in control group versus treatment group. While
vehicle treated tumors showed intense staining around lipid
droplets embedded in the tissues (Fig. 5E, left lower panel), MT19c
treated tumors showed lack of staining or partial/residual staining
(Fig. 5D, lower right panel). We noted the presence of four fatty
fields in the whole tissue section that were densely stained in the
vehicle treated tissue (only one of the fields is shown). However
only two fatty fields were detected in the drug treated xenograft
section and the p-ACC staining around them was significantly
lower than vehicle treated control tissues. The intensity of the
drug-treated tissues showed a mean value of 13121 units and 5.54
units of IOD compared to 23438 units of mean and 39.58 units of
IOD observed for vehicle treated xenograft tissue indicating
significant reduction in staining in MT19c treated xenograft
tumors.
MT19c reduced mitochondrial depolarization potential
and citrate homeostasis and causes LDH release in
ovarian cancer cells
FASN overexpression protects cells from apoptosis via stabili-
zation of mitochondrial membrane potential [31]. As shown in
Fig. 5B MT19c (1 mM) treatment reduced the transmembrane
mitochondrial potential of ,30% of SKOV-3 cell population
within 3 hrs of drug treatment and within 24 hrs more than 60%
of the cell population had lost membrane depolarization potential.
Therefore MT19c treatment significantly disabled mitochondrial
health of SKOV-3 cells leading to early cell death observed.
Since enzymes of citric acid cycle are located in the
mitochondrial matrix, we examined if citrate catabolism is
impaired due to disrupted mitochondria upon treatment with
MT19c in SKOV-3 cells. SKOV-3 cells were pretreated with
citrate (500 mM) for 1 hr and MT19c (0–1 mM) or vehicle was
applied for 24 hrs. While MT19c alone reduced the cell viability of
SKOV-3 cells strongly, citrate pretreatment rescued the cells from
MT19c induced cytotoxicity significantly even at a highly toxic
concentration of MT19c (1 mM) (Fig. 5C). Therefore, MT19c
disabled mitochondrial functions and blocked citrate catabolism in
the cells depriving the cells of the key building block (i.e. acetyl co-
A) for de novo fatty acid synthesis.
To determine if MT19c targeted the lactate synthesis machinery
of the glycolysis, we quantified the release of lactate dehydrogenase
(LDH) in three different EOC cell lines. LDH is a stable
cytoplasmic enzyme and cytotoxic agents induce a release of
LDH, the rate determining enzyme in the lactate synthesis. We
determined the release of LDH by a Cytotox 96H kit (Promega, cat
no-G1782). Our experiment revealed that MT19c at concentra-
tions of lower than 1 mM caused significant LDH release within
24 h in SKOV-3, CaOV-3 and OVCAR-8 EOC cells (Fig. 5D).
We infer based on LDH release that MT19c did not permit the
alternative metabolic pathway that feeds on lactate synthesis, in
addition to disrupting mitochondrial function and blocking the
fatty acid synthesis machinery.
mRNA from tumors was analyzed by Affymetrix microarray chips in triplicate and expression of genes was clustered by GSEA analysis. The difference
in expression of the genes from MT19c treated tumors was expressed as % of the control (6). (B) Expression of nuclear EGFR (nEGFR) in SKOV-
3 xenograft tissues treated with vehicle or MT19c. SKOV-3 xenografts were treated with MT19c or vehicle. Paraffin embedded tissues were
processed and stained with Alexafluor-conjugated phosphor-EGFR antibody and analyzed by confocal microscopy as described in Material and
Method section. EGFR is shown in the green along with nuclear stain DAPI. Magnification: 4062( C) Western blot analysis of phospho-EGFR and
phospho-PI-3K and expression of nuclear EGFR (nEGFR) in SKOV-3 cells. (Left panel): SKOV-3 cells were treated with 250 nM MT19c. PAGE
and Western blot analysis of cell lysates was carried out. Activated phospho-EGFR and phospho-PI-3K was visualized by immunoblotting using
primary antibodies recognizing cleaved fragments. As an internal standard for equal loading (50 mg total cell protein/lane) blots were probed with an
(-tubulin antibody. (right panel): expression of nuclear EGFR (nEGFR) in vehicle (upper panel), calcitriol (2 uM, middle panel) and MT19c (250 nM,
lower panel) treated SKOV-3 cells by immunofluorescence microscopy. EGFR is shown in green and right columns shows DNA (blue). Magnification:
40. (D) MT19c suppressed PI-3k kinase activity in SKOV-3 cells. SKOV-3 cells were treated with MT19c (0, 250 nM) for indicated time intervals.
Cell lysates were immunoprecipitated with an antibody specific for phospho-tyrosine and PI3K activity was determined with in vitro lipid kinase assay.
PIP-3 (phosphoinositide 3-phosphate), the phosphorylated end-product is shown. The bar graph shows the densitometric scanning results of a
representative experiment. (E): Identification of interaction between MT19c and PPARc using fluorescence polarization. Disruption of
binding between PPARc-LBD and fluorescent DRIP2 peptide by MT19c was investigated in the & presence andN absence of agonist GW929.
Controls were vehicle DMSO (m with agonist, # without agonist), . unlabeled DRIP2 peptide (positive control) and¤ fluorescent DRIP2 peptide by
itself (positive control).
doi:10.1371/journal.pone.0034443.g004
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(A-C) Western blot analysis of lipogenetic proteins in SKOV-3 cells. SKOV-3 cells were treated with 250 nM MT19c or vehicle for 24 h.
Analysis of the expression of proteins by western blotting of lysates with primary antibodies against fatty acid synthase (FASN), Acetyl co-A
carboxylase (ACC), phosphorylated ACC and AMPA was carried out (Material and Methods). Representative experiments are shown. As an internal
standard for equal loading (50 mg total cell protein/lane) blots were probed with an anti-(-tubulin antibody. (B) Mitochondrial transmembrane
depolarization-potential (DYm) analysis after MT19c treatment. SKOV-3 cells were treated for 3 or 24 h with 1 mM MT19c fixed and stained
with DiOC18(3) and FACS analysis carried out. The bar diagram depicts the number of non-fluorescing cells (%) with DYm loss. A representative
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Malonyl CoA is the main component that fatty acid synthase
converts into palmitates. We investigated if MT19c could restrict
the levels of malonyl CoA in ovarian cancer cells upon treatment.
Direct measurement of malonyl CoA in SKOV-3 cells by
reversed- phase HPLC of acid soluble extracts from vehicle or
drug treated cells confirmed that MT19c caused marked decrease
in malonyl CoA levels similar to the functions of TOFA a fatty
acid synthase inhibitor. Fig. 5F is a representative chromatograph
represents reference standard of malonyl CoA. Malonyl CoA is the
first of these to elute within 1 minutes. The estimation of the area
under curve of control (middle panel) and MT19c treated sample
(right panel) shows that MT19c treatment led to a marked
decrease (,60%) in malonyl CoA content in the drug treated
SKOV-3 cells compared to the untreated cells within 3 hours of
the treatment. The chemical identity of the malonyl-CoA was
independently confirmed by comparing the retention time (left
panel) and mass spectrum of malonyl-CoA (reference standard
from Sigma-Aldrich, USA) using a UV detector at 254 nM.
Discussion
Calcitriol and analogs displayed anti-tumor effects against
various cancer types [32]. However, in clinical trials calcitriol
and analogs displayed the lack of efficacy and caused hypercal-
cemia, hyperphosphatemia, and secondary effects such as vascular
calcification, nephrocalcinosis or adynamic bone disease [32 and
references cited therein]. These adverse outcomes have prompted
the development of less hypercalcemic and more efficacious
vitamin-D analogs. We developed a new approach to design
vitamin-D based molecules that are amenable to small molecule
library synthesis and subsequent high-throughput screening.
MT19c was designed by a targeted chemical modification of A-
ring of vitamin-D2 in just two efficient steps, in contrast to the
elaborated synthetic efforts needed for calcitriol or EB1089. We
incorporated a nitrogen- and oxygen-rich heterocyclic triazoline-
dione ring to balance the structure of the molecule in terms of
Lipinski’s rule [33]. In a preliminary study, we showed anti-cancer
actions of MT19c in cultured ovarian cancer cell models [20].
The present study shows that the novel compound MT19c is not
only the first true non-hypercalcemic vitamin-D derivative but also
reveals promising activities as an anti-tumor agent in various EOC
animal models. In vivo, MT19c treatment at 5 mg/kg bwt did not
elevate serum-calcium levels and showed no acute toxicity even at
400 mg/kg bwt. In human EOC derived xenografts the majority of
treated mice displayed complete response and extended tumor free
survival significantly (p,0.0001). In a syngeneic rat model all
animals treated with MT19c even at a low concentration (100–
500 mg/kg bwt) showed tumor regression and absence of ascites
formation, and cleared lesions in peritoneum and omentum.
MT19c did not cause hypercalcemia in animals even at 5006
dose of calcitriol. A VDR trans-activation and a VDR receptor
binding assay revealed that in contrast to calcitriol, MT19c
showed a biologically inconsequential weak VDR antagonism.
Lack of MT19c-VDR agonistic interaction was further supported
by the in silico molecular docking simulations performed for
MT19c with VDR crystal structure. Due to lower energy upside-
down docking of the bulkier and rigid MT19c in VDR-LBD, 15
amino acid interactions with MT19c are altered in comparison
with the structure of classical calcitriol-VDR interactions.
Furthermore, the docked structure of MT19c-VDR-LBD has a
altered position of helix 12 and 13, which is essential for the
interaction with coactivators. This behavior has been observed for
other VDR antagonists [21].
To identify the molecular target and unravel the mechanism of
action of MT19c in ovarian cancer models, we previously
conducted a genome wide mRNA analysis of the drug treated or
naı ¨ve tumors at three different treatment points (www.ncbi.nlm.
nih.gov (acc=GSE23616). A GSEA analysis to cluster genes
identified that lipid metabolism, molecular transport and small
molecule biochemistry genes such as ACACA, EGFR, FASN,
PRKAA2, PTEN, SCAP, SREBF1IPA involved in lipid synthesis
were most significantly downregulated (p=0.00000000055)
(Fig. 4A). Remarkably, these metabolic genes are implicated in
understanding the etiology of ovarian cancer and the development
of targeted therapies against these growth factors (e.g. EGFR), to
improve chemotherapy outcomes in ovarian cancer patients.
Epidermal growth factor receptor (EGFR) overexpression is
associated with poor prognosis, resistance to chemotherapy and
low survival rate in ovarian cancer [34]. EGFR enhances DNA
repair via catalytic subunit of DNA protein kinase (DNA-PKCs)
and promotes oncogenic signaling via PI-3K/AKT [35].Targeting
EGFR using pharmacological inhibitors such as Iressa has been
postulated to improve ovarian cancer therapy outcome and Iressa
responding patient population has been identified [36]. In our
experiment, fluorescence confocal microscopy showed that
MT19c treatment significantly inhibited EGFR activation in
ovarian xenograft tumors in animals compared to control (Fig. 4B).
Similarly, MT19c treatment did not induce EGFR translocation,
or phosphorylate EGFR in SKOV-3 cells (Fig. 4C)
EGFR activation leads to activation of PI-3kinase, via PDK1
and phosphorylation of S473 on the PKB/Akt that inhibits the
activity of pro-apoptotic proteins such as, Caspase-9 and GSK-3b
[37–38] Dysregulation of the PI-3kinase (PI3K) pathway has been
implicated in many human diseases and hyperactivation of this
pathway promotes tumorigenesis and chemoresistance [38].
Phosphoinositide 3,4,5,-trisphosphate (PIP3) is the main product
of PI3K activity. Small molecule antagonists of PIP3–PH domain
interactions (e.g. PITenins, PITs) suppressed the PI3K-PDK1-Akt
pathway, which triggers metabolic stress leading to apoptosis, and
validated the rationale of targeting PIP-3 signaling to inhibit
tumorigenesis [37,38]. MT19c inhibited not only PI-3kinase
phosphorylation, it also inhibited the synthesis of PIP-3 the main
product of PI-3k activity.
experiment is shown. (C) Effect of fatty acid synthase substrates on cytotoxicity of MT19c. SKOV-3 cells, preincubated with citrate (1 mM),
acetyl co-A (200 mM) for 1 hr and varying concentration of MT19c (0, 1 mM) were added and cells were incubated for 24 hrs and cell viability was
determined by MTS assay. (D) LDH release in SKOV-3 cells. SKOV-3 cells were treated with varying concentration of MT19c (0, 1 mM) were added
and cells were incubated for 24 hrs and LDH release estimated using cytotox kit (Promega). (E) expression of fatty acid synthesis proteins in
naı ¨ve and MT19c treated xenograft tumors. Expression of Fatty acid synthase (FASN) and phospho-acetyl CoA carboxylase (ACC) in vehicle (left
panel) and MT19c (5 mg/kg bwt, right panel) treated SKOV-3 xenografts was determined by a confocal immunofluorescence microscopy. FASN is
shown in green and phospho-ACC is shown in red. DNA is shown in blue. Magnification: 4062. (F) HPLC-MS quantification of malonyl-co-A content in
MT19c treated SKOV-3 cells. SKOV-3 cells were treated with vehicle or MT19c (500 nM) in serum free DMEM media. Acid soluble extracts were
analyzed by HPLC-MS. The area integrals and retention time of the malonyl CoA in control and treatment group was compared to the reference
standard (Sigma-Aldrich). (left panel): retention time of reference standard (Sigma Alrich, USA); (middle panel): retention time of malonyl CoA in the
vehicle treated SKOV-3 cells; (right panel): retention time of malonyl CoA in the MT19c (500 nM) treated SKOV-3 cells.
doi:10.1371/journal.pone.0034443.g005
Efficacy of MT19c in Ovarian Cancer Models
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34443To exert an oncogenic impact, EGFR over-expression directs
fatty acid synthesis enzymes (FASN and ACC) to facilitate aerobic
glycolysis and ignore oxidative phosphorylation for energy
production [6]. The endogenous fatty acid (FA) biogenesis,
catalyzed by FASN and its pathway components constitute a
major oncogenic stimulus that drives normal epithelial cells
progression towards malignancy [39]. Based on overactive FASN,
precursor lesions develop an adaptive metabolic response to
microenvironments [6]. The oncogenic action of FASN depends
on the oncogene EGFR, which induces FASN hyperactivation in a
bi-directional manner: i) maintaining incessant de novo fatty acid
synthesis via FASN that awards lipogenic and micro-environmen-
tal metabolic adaptive benefits to pre-lesion oncogenesis, chemo-
resistance and metastasis in ovarian cancer [40–41]; ii) averting
cellular toxicity arising due to end product of FASN action i.e.
palmitic acid by conversion of excess fatty acids (FA) to
triglycerides in PPAR-gamma dependent manner. MT19c treat-
ment downregulated FASN and ACC activation both in in-vitro
and in-vivo models of ovarian cancer. Abrogation of de novo
lipogenesis by MT19c occured PPAR-gamma independently.
The inhibition of fatty acid synthesis and the activity of FASN
and ACC are directly linked to the repudiation of citrate
homeostasis in mitochondria [5,6]. In tumor cells, mitochondria
accumulate lipophilic cations that increases their membrane
potential. The reduction of this increased membrane potential
either by chemotherapeutics or by stress stimuli causes cell cycle
arrest and apoptosis [42]. MT19c disrupted the mitochondrial
transmembrane depolarization potential within 3 hours of the
treatment indicating that citrate homeostasis was disrupted either
prior to fatty acid synthesis or concomitantly. Citrate is the
mitochondrial substrate that is converted to acetyl CoA catabol-
ically and the mitochondrial disruption by cytotoxic agents (e.g.
MT19c ) may reduce the supply of citrate, the key building block
for long chain fatty acid synthesis. MT19c inhibition of
mitochondrial function and citrate catabolism was directly proven
by reduction in cytotoxicity of MT19c upon replenishing the
SKOV-3 cells with citrate post MT19c treatment but not with
acetyl Co-A, malonyl Co-A or recombinant Acetyl Co-A
carboxylase enzyme. MT19c treatment also caused LDH release
and blocked lactate synthesis in SKOV-3, CaOV-3 and OVCAR-
8 cells. LDH release is a direct measure of a cytotoxic response of
chemotherapeutic drugs. Further the direct measurement of
malonyl CoA derivatives in SKOV-3 cells by reversed- phase
HPLC of acid soluble extracts from vehicle or drug treated cells
confirmed that MT19c caused marked decrease in malonyl CoA
levels similar to the functions of TOFA a fatty acid synthase
inhibitor [43].
In conclusion, we have described a new design approach to
non-hypercalcemic vitamin-D derivatives bestowed with potent
anticancer efficacy without any toxicity. MT19c is the first non-
hypercalcemic vitamin-D derivative that revealed promising anti-
cancer efficacies in two independent EOC animal models. MT19c
targets the cancer cell metabolism machinery, specifically FASN
functions and abrogates de novo lipogenesis, the hallmark of cancer
cells. This study therefore provides the rationale for developing
novel vitamin-D analogs that target de novo fatty acid synthesis in
ovarian cancer.
Materials and Methods
Cell culture and cytotoxicity assay
SKOV-3, OVCAR-3 and OVCAR-8 cells were purchased
from American Tissue Culture Collection (ATCC) (www.atcc.org)
and maintained as described previously [44]. No de novo cell lines
were developed for this study. Quantification of MT19c induced
cytotoxicity to a panel of ovarian cancer cell-lines (SKOV-3,
OVCAR-3 and OVCAR-80) was determined by a Cytotox 96H
cytotoxicity assay kit (Promega, Madison, WI, USA). Experiments
were performed in triplicates; data are expressed as the mean of
the triplicate determinations (X6SD) of a representative experi-
ment in % of absorbance by samples with untreated cells
(=100%).
Hypercalcemia and acute toxicity determination in mice
All animal experiments, with the exception of acute toxicity
experiments, were performed in the animal facilities of Rhode
Island Hospital (RIH) with strict adherence to the guidelines of the
Animal Welfare Committee of RIH and Women & Infants
Hospital (WIH) in accordance with the guidelines set by the NIH
in the care and use of laboratory animals (Laboratory Animal
Protection Approval: A3922-01; CMTT: 0061-07). The Animal
welfare committee (RIH and WIH) specifically approved this
study.
Thirteen six-week old female nude mice (nu/nu strain code
088/homozygous, 25 g average weight) (Charles River Laborato-
ries, Wilmington, MA, USA) were randomly assigned to a control
group (8 animals) or treatment group (8 animals each for MT19c
and calcitriol). Vehicle (PBS/2.5% EtOH) or MT19c at 5 mg/kg
bwt or calcitriol (10 mM) in 0.2 ml of vehicle was administered
intraperitoneally (IP) every other day for 35 days. Animal were
monitored daily and weights were measured biweekly. Blood
samples were collected on the day 35 by cardiac puncture
(endpoint). Calcium concentration analysis was performed by
IDEXX Laboratories Inc. (North Grafton, MA).
The acute toxicity study (400, 200, 100 mg/kg bwt MT19c, IP,
day 0, one mouse each) was performed by the National Cancer
Institute (NCI) Developmental Therapeutics Program (DTP)
(www.dtp.nci.nih.gov, athymic nude mice). For details of the
method refer Supporting Information S1.
EOC Xenograft Model in mice
Animal experiments were carried out in the animal facilities of
Rhode Island Hospital (RIH), RI, USA with strict adherence to
the guidelines of the Animal Welfare Committee of Rhode Island
Hospital (RIH) and Women and Infants Hospital of Rhode Island
(Laboratory Animal Protection Approval: A3922-01; CMTT:
0061-07). Four to six week-old immunodeficient nude mice (NU/
NU; strain code 088/homozygous) (Charles River Laboratories,
Wilmington, MA) were maintained at a temperature of 2261uC
and a relative humidity of 5565%, with a 12 h light/dark cycle.
SKOV-3 cells were cultured to 80% confluence, washed in PBS
twice, harvested by trypsination, pooled in complete medium,
washed in PBS twice, and 2610
6 cells/inoculate were suspended
in 0.1 ml of matrigel and inoculated subcutaneously in the flank of
mice. Mice with developing tumors after two weeks were
randomly assigned to experimental groups. MT19c was prepared
as a stock solution of 1 mM in 100% EtOH and diluted 1:40 in
PBS for administration. Mice were treated intraperitoneally every
other day with either vehicle control (control group; 8 animals) or
300 ml (5 mg/kg bwt) of MT19c (n=20) for 60 days. Mice were
weighed and tumor size calculated using a caliper every 5 days.
Survival curves were estimated using Kaplan-Meier method.
Evaluation of efficacy of MT19c in a syngeneic EOC
model in rats
Eight week-old female rats (Fisher 344, average weight 140 g;
Charles River Laboratories, Canada) were divided in two
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500 mg/kg bwt, n=3) and one control group (n=12). Rat EOC
NuTu-19 cells (5610
6 cells/inoculate) were suspended in PBS and
injected IP. Rats were monitored and after 3 weeks treated IP
every day with either vehicle (PBS/2.5% EtOH) control or 500 ml
(100 or 500 mg/kg bwt) MT19c for 12 days before animals were
euthanized, tumor tissues harvested, omental weight and hemor-
rhagic ascites volume were recorded.
Structural Modeling and Molecular Docking Simulation
(MDS)
MDS was carried out using the AutoDock 4.0 program with the
structure of MT19c and calcitriol-liganded VDR (PDB ID: 1DB1)
provided by the Protein Data Bank [22]. For MT19c docking
simulation the ligand in the binding pocket of VDR was removed.
MDS was carried out applying the Lamarckian genetic algorithm
[23]. A population size of 150 and 2,500,000 energy evaluations
were used for 50 local search runs. The docking area was defined by
a box, with grid spacing of 0.375 A ˚ and the dimension of
50650650 points along the x, y and z axes. The conformation
withthelowestdockedenergywaschosenasapossiblecandidatefor
MT19c. Images of structures weregenerated using UCSF Chimera.
Analysis of VDR-modulation by MT19c
Effect of MT19c on VDR was examined using a commercially
available VDR transcription assay GeneBLAzer (Invitrogen).
Experimental details of this assay are provided in the Supporting
Information S1.
Determination of agonistic and antagonistic properties
of MT19c using a PPAR-gamma–coactivator binding
assay
The assay has been described in detail previously [45]. Briefly,
pET15b-PPARc-LBD expression plasmid, encoding the PPARc-
LBD (amino acids 173–475) was a generous gift from Gabor J.
Tigyi (University of Tennessee, Memphis). PPARc-LBD was
expressed in BL21 (DE3) (Invitrogen), purified by affinity
chromatography, and stored at 280uC in buffer (50 mM Tris
(pH 8.0), 25 mM KCl, 2 mM DTT, 10% glycerol, 0.01% NP-40).
For the assay, MT19c were serially diluted in DMSO and 100 nl
of each concentration was transferred into 20 mL protein buffer
(20 mM TRIS (pH 7.5), 100 mM NaCl, 0.01% NP-40, 2%
DMSO, 10 nM DRIP2 (CNTKNHPMLMNLLKDNPAQD)
labeled with Texas-Red maleimide, and 1 mM PPARc-LBD) in
the presence and absence of rosiglitazone (5 mM) in quadruplet
using black 384 well plate (Costar, #3658) (see Supporting
Information S1). The samples were allowed to equilibrate for two
hours. Binding was then measured using fluorescence polarization
(excitation 595 nm, emission 615 nm) using a M1000 plate reader
(Tecan). The experiments were evaluated using GraphPad Prism
5, and IC50 values were obtained by fitting the data to an
equation (Sigmoidal dose-response-variable slope (four parame-
ters). Values are given as the mean values of two independent
experiments with a 95% confidence interval.
Immunohistochemical analysis of tumors
Immunohistochemical staining was performed on paraffin-
embedded slides of the vehicle or drug treated tumor specimens
(thickness 5 mm). Tissuesectionsweredeparaffinized and rehydrated
with serial ethanol dilutions of 100, 95 and 70%. Heat-induced
antigen retrieval was then performed using DAKO Antigen
Retrieval Solution for 20 min. Tissue sections were blocked with
Normal Goat Blocking Serum (Vector Laboratories) for 60 min at
room temp before incubating with primary antibodies for phospho-
EGFR (Rand D systems, MN, USA)(1:50 dilution),phospho-actetyl
CoA carboxylase (1:200), and fatty acid synthase (1:200) (Cell
Signaling Technologies) in a humidified chamber overnight at 4uC.
Secondary antibodies (DyLight 594 goat anti-rabbit IgG, Jackson
ImmunoResearch Laboratories, INC. and Alexa Fluor 594 goat
anti-mouse IgG at 1:500, Invitrogen) were applied and incubated for
60 min for 1 hour at room temperature in the dark. Vectashield
media with DAPI (Vector Laboratories) was used to mount cover-
slips for further analysis. Sixteen bit images were acquired with a
Nikon E800 microscope (Nikon Inc. Mellville NY) using a 406
PlanApoobjective. ASpotIIdigitalcamera(DiagnosticInstruments,
Sterling Heights MI) was used to acquire the images (see Supporting
Information S1). The cameras built-in green filter was used to
increase imagecontrast. Camerasettingswerebased on the brightest
slide. All subsequent images were acquired with the same settings.
Image processing and analysis was performed using iVision
(BioVisionTechnologies,version10.4.11,Exton,PA.)imageanalysis
software.Positive stainingwas defined throughintensitythresholding
and integrated optical density (IOD) was calculated by examining
the thresholded area multipliedbythe mean.Allmeasurementswere
performed in pixels. Confocal images were acquired with a Nikon
C1si confocal (Nikon Inc. Mellville NY.) using diode lasers 402, 488
and 561. Serial optical sections were performed with EZ-C1
computer software (Nikon Inc. Mellville, NY). Z series sections were
collected at 0.3 mmw i t ha4 0 6PlanApo lens and a scan zoom of 2.
The gain settings were based on the brightest slide and kept constant
between specimens. Deconvolution and projections were done in
Elements (Nikon Inc. Mellville, NY) computer software.
Mitochondrial transmembrane-depolarization potential
assay
SKOV-3 cells (1610
6) were seeded in a 100 mm
2 petri-dish and
treated with vehicle (EtOH) or MT19c (1 mM) for 3 or 24 h and
the assay carried out as described earlier [44].
Microarray data
To identify the molecular targets of MT19c in ovarian cancer
cells, a Gene Set Enrichment Analysis (GSEA) analysis of the
genome wide mRNA of vehicle treated (control) and MT19c
treated tumors on day-8, day-16 and day-30 was conducted in
triplicates using Affymetrix Human Gene 1.0 ST Array (Affy-
metrics, Santa Clara, CA). Microarray data is MIAME compliant.
The raw expression data has been deposited at address: www.ncbi.
nlm.nih.gov (acc=GSE23616)
Western blot analysis
SKOV-3 cells were seeded into 6-well plates (3610
5cells/dish)
before treatment with MT19C (1 mM). Preparation of cell lysates,
PAGE and immunoblotting with appropriate antibodies pur-
chased from Cell Signaling technology (Beverly, MA, USA) was
carried out as described previously [44]
HPLC quantification of malonyl CoA in SKOV-3 cells
SKOV-3 cells seeded in 100 mm
2 dishes (3610
6cells/dish) were
treated with either vehicle or MT19c (250 nM) in serum free
conditions. Cellular content of malonyl co-A was analyzed by
HPLC following the literature procedure [43] described briefly in
the Supporting Information S1.
Statistical Analyses
Data analysis was performed with STATA 9 (StataCorp, College
Station, TX, USA) and SAS 9.1 (SAS Institute, Cary, NC, USA).
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statistically significant. Means were compared by Student’s T-test
with adjustment for unequal variances as appropriate. Tumor
growth rates in the MT19c-treated miceand controls wereanalyzed
by repeated measures linear regression. A first-order autoregressive
covariance patternwasused tomodelthewithin-subjectcorrelation.
Treatment group and evaluation days were entered as factors in
model along with their interaction term. Tumor growth was also
examined by Kaplan-Meier analysis and the log-rank test (see
Supporting Information S1). The outcome was growth of 10 mm or
more, and follow-up was censored at the end of evaluation (60 days)
or at the time of euthanasia. The proportional hazards assumption
was checked by graphical inspection.
Supporting Information
Supporting Information S1
(DOC)
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